Applied Biosystems and Eppendorf Announce Licensing Agreement
News Nov 14, 2005
Under the agreement, Eppendorf will have the right to manufacture and sell real-time thermal cyclers in the research and applied fields.
"This agreement with Eppendorf further validates the significance of Applied Biosystems' real-time thermal cycler technology," said Paul D. Grossman, Ph.D., Esq., Vice President, Strategic Planning, Business Development and Intellectual Property for Applied Biosystems.
"We may consider entering into additional licenses with high quality vendors under the right terms."
"We are pleased to announce our agreement with Applied Biosystems," said Klaus Fink, CEO and President of Eppendorf AG.
"We are committed to providing our customers with access to technologies that are of greatest importance for the life sciences sector."
"Our new product generation of real-time cyclers ensures best practices in laboratories in terms of productivity, simplicity, and ease of use."
The license to Eppendorf is based on U.S. Patent No. 6,814,934 and foreign equivalents.
The U.S. Patent & Trademark Office (USPTO) granted Applera this fundamental patent pertaining to real-time PCR instrumentation in November 2004.
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018